Inhaled seralutinib demonstrated clinical activity in high-risk pulmonary arterial hypertension patients despite missing its primary phase 3 endpoint.
Boston, MA Many patients with apparent sporadic primary pulmonary hypertension (PPH) have actually been misdiagnosed and have a familial form of the disease, according to a report in the August 2, ...
Gossamer Bio (NASDAQ:GOSS) reported top-line results from PROSERA, its global phase III registrational study evaluating inhaled seralutinib in patients with pulmonary arterial hypertension (PAH). Comp ...
Ventavis® is an established inhaled prostacyclin analogue for the treatment of primary pulmonary hypertensionAcquisition reinforces Essential ...
Gossamer Bio's phase three study of its seralutinib drug for Pulmonary Arterial Hypertension did not meet the statistical threshold for its primary endpoint. Shares fell 82% to 38 cents in premarket ...
A phase 3 study of Gossamer Bio’s seralutinib in pulmonary arterial hypertension (PAH) has missed its primary endpoint, triggering a 77% crash in the biotech’s share price. The company has paused ...
Gossamer Bio, Inc. (Nasdaq: GOSS) a biopharmaceutical company focused on the development and commercialization of seralutinib ...
Pulmonary arterial hypertension (PAH) is a type of high blood pressure in the arteries that go from your heart to your lungs. It happens when these arteries become narrow or blocked, making it harder ...
9. Ahearn GS, Tapson VF, Rebeiz A, Greenfield JC Jr. Electrocardiography to define clinical status in primary pulmonary hypertension and pulmonary arterial hypertension secondary to collagen vascular ...
Pulmonary arterial hypertension (PAH) is a type of high blood pressure in the arteries that go from your heart to your lungs. It happens when these arteries become narrow or blocked, making it harder ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results